LLY

1,007.72

+1.1%↑

JNJ

230.91

+0.5%↑

UNH

394.77

-0.71%↓

AZN

182.41

-1.25%↓

NVS

149.46

+0.18%↑

LLY

1,007.72

+1.1%↑

JNJ

230.91

+0.5%↑

UNH

394.77

-0.71%↓

AZN

182.41

-1.25%↓

NVS

149.46

+0.18%↑

LLY

1,007.72

+1.1%↑

JNJ

230.91

+0.5%↑

UNH

394.77

-0.71%↓

AZN

182.41

-1.25%↓

NVS

149.46

+0.18%↑

LLY

1,007.72

+1.1%↑

JNJ

230.91

+0.5%↑

UNH

394.77

-0.71%↓

AZN

182.41

-1.25%↓

NVS

149.46

+0.18%↑

LLY

1,007.72

+1.1%↑

JNJ

230.91

+0.5%↑

UNH

394.77

-0.71%↓

AZN

182.41

-1.25%↓

NVS

149.46

+0.18%↑

Home・Akcijų sąrašas・AbbVie Inc

AbbVie Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

212 1.45

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

210.09

Max

214.84

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.1B 697M
Pardavimai	-1.6B 15B
P/E Sektoriaus vid.	99.402 51.415
Pelnas, tenkantis vienai akcijai	2.65
Dividendų pajamingumas	3.34
Pelno marža	4.646
Darbuotojai	57,000
EBITDA	-635M 4.7B

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+21.9% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	3.34% 2.34%
Kitas uždarbis	2026-07-30
Kitas dividendų mokėjimo data	2026-05-15
Kita Ex Dividend data	2026-07-14

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	9.2B 358B
Ankstesnė atidarymo kaina	210.55
Ankstesnė uždarymo kaina	212

Naujienos nuotaikos

By Acuity

18%

82%

36 / 346 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

180.37 / 195.54 Palaikymas ir pasipriešinimas

AbbVie Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-29 12:38; UTC

Uždarbis

AbbVie Raises Fiscal Year Guidance on Immunology, Neuroscience Growth

2026-02-04 13:20; UTC

Uždarbis

AbbVie 4Q Revenue Rises on Immunology Growth

2026-04-29 12:41; UTC

Uždarbis

AbbVie Beats Earnings Estimates, Boosts 2026 Outlook. What It Means for the Stock. -- Barrons.com

2026-04-29 12:23; UTC

Uždarbis

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

2026-04-29 11:50; UTC

Uždarbis

AbbVie Raising Adjusted EPS Guidance for FY26 >ABBV

2026-04-29 11:49; UTC

Uždarbis

AbbVie 1Q Global Humira Rev $688 M >ABBV

2026-04-29 11:48; UTC

Uždarbis

AbbVie 1Q Global Rinvoq Rev $2.119 B >ABBV

2026-04-29 11:47; UTC

Uždarbis

AbbVie 1Q Global Net Rev From Oncology Portfolio $1.63B >ABBV

2026-04-29 11:47; UTC

Uždarbis

AbbVie 1Q Global Skyrizi Rev $4.48B >ABBV

2026-04-29 11:47; UTC

Uždarbis

AbbVie 1Q Global IMBRUVICA Rev $556M >ABBV

2026-04-29 11:47; UTC

Uždarbis

AbbVie 1Q EPS 39c >ABBV

2026-04-29 11:47; UTC

Uždarbis

AbbVie 1Q Net $695M >ABBV

2026-04-29 11:47; UTC

Uždarbis

AbbVie 1Q International HUMIRA Rev $331M >ABBV

2026-04-29 11:47; UTC

Uždarbis

AbbVie 1Q Rev $15B >ABBV

2026-04-29 11:47; UTC

Uždarbis

AbbVie 1Q Adj EPS $2.65 >ABBV

2026-04-29 11:47; UTC

Uždarbis

AbbVie 1Q U.S. HUMIRA Rev $357M >ABBV

2026-04-29 11:47; UTC

Uždarbis

AbbVie Sees FY Adj EPS $14.08-Adj EPS $14.28 >ABBV

2026-02-04 19:38; UTC

Uždarbis

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

2026-02-04 16:19; UTC

Uždarbis

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

2026-02-04 15:18; UTC

Uždarbis

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

2026-02-04 13:18; UTC

Uždarbis

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

2026-02-04 12:48; UTC

Uždarbis

AbbVie 4Q U.S. HUMIRA Rev $897M >ABBV

2026-02-04 12:48; UTC

Uždarbis

AbbVie 4Q Rev $16.62B >ABBV

2026-02-04 12:48; UTC

Uždarbis

AbbVie 4Q Global IMBRUVICA Rev $671M >ABBV

2026-02-04 12:48; UTC

Uždarbis

AbbVie 4Q Global Skyrizi Rev $5.01B >ABBV

2026-02-04 12:48; UTC

Uždarbis

AbbVie 4Q Net $1.82B >ABBV

2026-02-04 12:48; UTC

Uždarbis

AbbVie 4Q Adj EPS $2.71 >ABBV

2026-02-04 12:48; UTC

Uždarbis

AbbVie 4Q Global Net Rev From Oncology Portfolio $1.66B >ABBV

2026-02-04 12:48; UTC

Uždarbis

AbbVie 4Q International HUMIRA Rev $349M >ABBV

2026-02-04 12:48; UTC

Uždarbis

AbbVie Sees FY Adj EPS $14.37-Adj EPS $14.57 >ABBV

Akcijų palyginimas

Kainos pokytis

AbbVie Inc Prognozė

Kainos tikslas

By TipRanks

21.9% į viršų

12 mėnesių prognozė

Vidutinis 254.17 USD 21.9%

Aukščiausias 298 USD

Žemiausias 203 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines AbbVie Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

20 ratings

Pirkti

Laikyti

Parduoti

Remiantis 20 analitikų, pateikusių AbbVie Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

180.37 / 195.54Palaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There is one bearish event.

Rinkos nuotaikos

By Acuity

36 / 346 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.